liraglutide, Victoza (cont.)
Omudhome Ogbru, PharmD
Omudhome Ogbru, PharmD
Dr. Ogbru received his Doctorate in Pharmacy from the University of the Pacific School of Pharmacy in 1995. He completed a Pharmacy Practice Residency at the University of Arizona/University Medical Center in 1996. He was a Professor of Pharmacy Practice and a Regional Clerkship Coordinator for the University of the Pacific School of Pharmacy from 1996-99.
Medical and Pharmacy Editor:
There have been reports of acute pancreatitis associated with the use of liraglutide. Patients developing severe, persistent abdominal pain that might be caused by pancreatitis, should seek prompt medical attention. If pancreatitis is suspected, liraglutide should be discontinued and not started again until the presence of pancreatitis has been excluded.
Liraglutide can cause thyroid tumors that occur more frequently at higher doses and with longer duration of treatment. Since liraglutide is a synthetic protein patients may develop antibodies to liraglutide. Liraglutide antibodies may reduce the effectiveness of liraglutide.
GENERIC AVAILABLE: No.
PREPARATIONS: Multiple dose pre-filled pen: 18 mg in 3 ml (6 mg/ml)
STORAGE: Liraglutide should be refrigerated between 2-8 C (36-46 F) prior to first use. After the first use it can be stored at room temperature 15 C - 30 C (59 F - 86 F) or refrigerated at 2 C - 8 C (36 F - 46 F).
DOSING: Liraglutide is injected under the skin of the abdomen, thigh, or upper arm. Each pre-fiilled pen can deliver 0.6, 1.2, and 1.8 mg doses. The initial dose is 0.6 mg daily for one week. The initial dose helps the body to build a tolerance to stomach related side effects. It is not effective for controlling blood glucose. After one week the dose is increased to 1.2 mg daily. The maximum dose is 1.8 mg daily.
DRUG INTERACTIONS: Liraglutide slows down transit of food and drugs through the intestine and, therefore, may reduce the absorption of drugs that are taken orally. Although liraglutide did not significantly affect the absorption of oral dugs tested in studies, it is still prudent to separate administration of liraglutide and oral medications. Combining liraglutide with insulin or drugs that stimulate release of insulin (for example, glyburide [Micronase, Diabeta, Glynase, Prestab]) may increase the occurrence of low blood sugar (hypoglycemia). The dose of insulin or the insulin release stimulating drug should be reduced.
PREGNANCY: There are no adequate studies of liraglutide in pregnant women. Most experts agree that insulin is the drug of choice in pregnant women with diabetes.
NURSING MOTHERS: There are no adequate studies of liraglutide in nursing mothers, and it is not known whether liraglutide is excreted in human breast milk.
Medically reviewed by Eni Williams, PharmD
REFERENCE: Reference: FDA Prescribing Information
Medically Reviewed by a Doctor on 4/3/2015
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Need help identifying pills and medications?
Back to Medications Index
- Allergic Skin Disorders
- Bacterial Skin Diseases
- Bites and Infestations
- Diseases of Pigment
- Fungal Skin Diseases
- Medical Anatomy and Illustrations
- Noncancerous, Precancerous & Cancerous Tumors
- Oral Health Conditions
- Papules, Scales, Plaques and Eruptions
- Scalp, Hair and Nails
- Sexually Transmitted Diseases (STDs)
- Vascular, Lymphatic and Systemic Conditions
- Viral Skin Diseases
- Additional Skin Conditions